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Abstract
Increased activation of alveolar macrophage, neutrophil and mast cell has been proven in
cigarette smoking (CS)-related lung disorders (CSLD). An increased production of cysteinyl-
leukotrienes (LTs), which are mediators secreted from the mentioned cells, in response to CS
has been shown in humans. The protective effect of LT1 receptor-1 antagonist (LTR-1AT) on
CSLD is, however, not known. In this study we aimed to determine whether there is any protec-
tive effect of a LTR-1AT, montelukast (MK), on CSLD in Wistar rats. Nine controls and twenty-
three smoke-exposed rats were enrolled into this study. Controls were exposed to non-filtered air,
and the smoke-exposed rats were exposed to CS for 6 h/day, 6 days/week for three weeks. The
CS-exposed rats were also treated with 0.1 mg/kg/day of MK or saline. Morphometric criteria
for lung injury were determined as the mean linear intercept of alveolar septa (Lm), the volume
density of alveolar septa (Vvspt) and the density of the alveolar surface area per unit volume of
lung parenchyma (Sva.pa). Lung mast cells (LMC), which are a major source of LTs, were also
counted. Results showed that Lm of the control group was significantly lower and Vvspt, Sva.pa
of the controls were significantly higher compared to those of the CS-exposed groups. Animals
treated with MK had significant protection against CSLD. Lm was significantly higher and Vvspt,
Sva.pa were lower in the saline group than in the MK-treated group. The number of LMC in the
CS-exposed groups was also significantly higher than that in the control group. Based on these
results, one can suggest that some part of the pathogenesis of CSLD may be related to an en-
hanced LTs synthesis and LTR-1AT. Therefore, montelukast may protect against active or passive
smoking-induced lung injury and related disorders.
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Increased activation of alveolar macrophage, neutrophil and mast cell has been proven in cigarette smoking (CS)-related lung disorders (CSLD). An increased production of cysteinyl-leukotrienes
(LTs), which are mediators secreted from the mentioned cells, in response to CS has been shown in humans. The protective eﬀect of LT1 receptor-1 antagonist (LTR-1AT)on CSLD is, however, not known. In this study we aimed to determine whether there is any protective eﬀect of a LTR-1AT,
montelukast (MK), on CSLD in Wistar rats. Nine controls and twenty-three smoke-exposed rats were enrolled into this study. Controls were exposed to non-ﬁltered air, and the smoke-exposed rats were exposed to CS for 6 h/day, 6 days/week for three weeks. The CS-exposed rats were also treated with 0.1 mg/kg/day of MK or saline. Morphometric criteria for lung injury were determined as the mean linear intercept of alveolar septa (L?), the volume density of alveolar septa (V???)and the density of the alveolar surface area per unit volume of lung parenchyma (S????). Lung mast cells
(LMC), which are a major source of LTs, were also counted. Results showed that L?of the control group was signiﬁcantly lower and V???, S????of the controls were signiﬁcantly higher compared to those of the CS-exposed groups. Animals treated with MK had signiﬁcant protection against CSLD.
L?was signiﬁcantly higher and V???, S????were lower in the saline group than in the MK-treated group. The number of LMC in the CS-exposed groups was also signiﬁcantly higher than that in the control group. Based on these results, one can suggest that some part of the pathogenesis of CSLD may be related to an enhanced LTs synthesis and LTR-1AT. Therefore, montelukast may protect against active or passive smoking-induced lung injury and related disorders.
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E xposure to cigarette smoking (CS)is a signiﬁcant risk factor for chronic obstructive lung disease
(COLD)in adulthood and plays an important role in the development of wheeze and asthma in childhood［1, 2］.
Although the link between CS and smoking-related lung disease has been poorly understood, recent studies have
 
suggested that inﬂammatory mechanisms may be respon-
sible［3, 4］. As in patients with COLD and asthma,
increased numbers of neutrophils, macrophages, mast cell etc have been found in the bronchioli of smokers［4,
5］. Moreover, the mucosa of the bronchioli in COLD and asthma patients are characterized by inﬂammatory cell inﬁltration and increased synthesis of inﬂammatory media-
tors from these cells, such as leukotrienes［1, 6］.
Cysteinyl-leukotrienes (LTs), including LTC4, LTD4 and LTE4, play many roles in smoking-related lung
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diseases［7, 8］. Fauler et al. showed that CS stimu-
lates and enhances LTs production in humans, and they claimed that some of the adverse eﬀects of CS exposure on pulmonary structures might be related to an enhanced LTs synthesis［7］. LTs are synthesized from the 5-lypoxygenase pathway of arachidonic acid metabolism by 5-lypoxygenase (5-LO)［8-11］. Lung mast cells
(LMC)are an important source of LTs in pulmonary parenchyma［11］. Current data suggest that the biologi-
cal eﬀects of LTs appear via a single receptor for all the LTs, LTs receptor-1［11］. Increased numbers of mast cell, neutrophils and T-lymphocytes and an enhanced activation of alveolar macrophages, which are the major cellular sources of LTs, have been shown in active smokers. These cells may also be responsible for CSLD
［4, 7, 8, 11, 12］. Therefore, active or passive CS-
induced LTs secretion from inﬂammatory cells in lung parenchyma may be responsible for CSLD and airway hyperreactivity. However, it is not known whether inhibi-
tion of the eﬀects of LTs by LTs receptor-1 antagonist
(LTR-1AT)protects against active or passive CSLD.
Accordingly, we designed the present study to clarify whether montelukast, which is a potent LTR-1AT, could protect against CS-induced lung injury in CS-exposed Wistar albino rats.
Materials and Methods
 
Thirty-two 210±25 gram, 12- to 17-week-old female Wistar rats were used in this study.
None of them had any sign of infection, respiratory disorders or pneumonia. After a 2-week quarantine and acclimatization period, twenty-three animals were exposed to mainstream CS for 6 h/day, 6 days/week for 3 weeks.
Nine rats were used as the controls, and they were exposed to non-ﬁltered room air. CS-exposed animals and controls were fed a pelleted ration and provided water ad libitum. The signed study protocol was approved by the Celal Bayar University Ethics Committee and carried out in accordance with our institutional Policies and Guide-
lines for the Care and Use of Laboratory Animals.
The CS-exposed rats were divided into 2 groups. Twelve CS-exposed animals were treated with montelukast(Sin-
gulair, Merck-Sharp Dohme Co., WA, USA), an oral and potent LTR-1AT, at a dosage of 0.1 mg/kg/day by oral route for 3 weeks. The remaining 11 CS-exposed rats were treated with the same volume of oral saline
 
during the same period. None of the control animals received any medication. At the end of the study period,
all animals were sacriﬁced and their lung tissues were processed for histologic and morphometric examination to reveal CS-induced lung injury and LMC counts.
Passive CS exposure was performed with non-ﬁltrated smoke fume using a previously described method［13］. One 50-cm?
puﬀper minute from a non-ﬁltered, low-quality cigarettes was generated by a smoking device delivered to a 75×
75×50-cm whole-body exposure chamber constructed of polyethylene material and joined to the smoking device.
Controls were sham-exposed to non-ﬁltered room air.
CS-exposed and control animals were sacriﬁced at the end of the third week. Their lungs were immediately extracted by tho-
racoabdominal incision and separated at the level of the trachea. All lungs were perfused, via the trachea, with Cornoy ﬁxative and 10  formaldehyde overnight. After the ﬁxation period, nonpulmonary tissues were dissected from the pulmonary structure and embedded in paraﬃn.
The left lungs were systematically sectioned in a dorsoventral-transverse direction at 3-mm intervals, with the ﬁrst slice randomly positioned within 3 mm of tissue as described previously［14］. Blocks were sliced into 5-μm thick sections using a microtome. Formalin-ﬁxed preparations were stained with haematoxylin-eosin, and Cornoy-ﬁxed preparations were stained with toluidine blue.
Histopathologic and morphometric examinations of lungs were performed on haematoxylin-eosin-stained lung sec-
tions by using a digital computerized system adapted to light microscopy. In this system, ﬁelds were examined at a magniﬁcation of 10x for the eyepiece and a 40-or 100-objective lens on a digital camera (Samsung SAG 410PA, Seoul, Korea)interfaced with a light microscope
(Olympus BX40F-3, Tokyo, Japan). Using these instru-
ments, we obtained digitized images of the chosen lung ﬁelds and transported them to the computer. Digitized images were saved using Microsoft image software
(WinTV 4.7.6255, Hauppage Computer Works, NY,
USA). The objective of the light microscope was random-
ly positioned within the extreme dorsomedial region of a section, and the area was marked as number 1, 2, etc.
This processing was made in a zigzag pattern (ﬁrst laterally, then ventrally, then medially)repeatedly, and the objective was moved across the entire section. Every
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third ﬁeld was selected and was changed to provide a magniﬁcation of 200x prior to creation of a software image. All morphometric measurements to demonstrate CS-induced changes in parenchyma were performed by the image software using saved digitized images.
A computer-
generated quadrangle grid containing 100 spaced points and sine-wave straight lines on a perpendicular and dorsoventral axis was placed on the projections. The length of a straight line was measured, by using the total augmentation ratio, as 18μin real-time. The accepted criteria that demonstrated CS eﬀects on pulmonary paren-
chyma were alveolar airspace enlargement and tissue loss,
as described previously［14, 15］. The most commonly used morphometric indicator of airspace enlargement is the mean linear intercept of alveolar septa(L?, inμm).
Thus, L?was measured as described by Dunnill et al
［16］. Also, the most commonly used criteria for tissue loss are the measurement of volume density of alveolar septa(V???, )and the density of the alveolar surface area per unit volume of lung parenchyma(S????, mm??)
calculated by using L?as described previously by March et al［14］.
Since the most important source of secreted LTs from lung parenchyma is mast cells, we counted LMC in all sections of toluidine blue-stained samples. Enumeration of LMC was perform-
ed with 10x eyepiece and a 40x objective lenses. All the LMC in a single section were counted and categorized as
“intact”(identiﬁable by their methachromatic granules)or
“degranulated”(partially degranulated LMC having vis-
ible extracellular granules) cells as previously reported
［17］. A total LMC count was obtained by using a magniﬁcation ratio and an identically magniﬁed micrometer scale image as an index of magniﬁcation. Then, the mean total LMC count was calculated and expressed as per mm?. In addition, the degranulation ratio of LMC, as an activation criteria of mast cells, was accounted as a percent( ).
Data including L?, V??, S????and LMC count were expressed as means±SDs. Mor-





None of the animals had any life-threatening events during the study, and body weights of members of all groups at the end of study were not signiﬁcantly diﬀerent from weights at the beginning of the study. In the general viewing by light microscopy, there were no signiﬁcant pathological changes in the pulmonary structure of the control rats
(Fig. 1a). The lungs from CS-exposed untreated rats had diﬀuse and nonuniform alveolar airspace enlargement,
decreasing of alveolar septal thickening, irregular widen-
ing of alveolar ducts, increased visceral pleural thickening and multifocally distributed intraalveolar or parenchymal bleeding (Fig 1b). Most of the alveoli were distorted and had prominent alveolar septal attenuation (Fig. 1b).
However, the mentioned parenchymal changes in rats treated by MK were not as severe as those in the untreated CS-exposed group(Fig. 1c).
A two-way ANOVA (3 groups)of morphometric mea-
surements showed signiﬁcant airspace enlargement and diﬀerences by means of the increased L?and decreased V???and S????of both CS-exposed animals and control subjects (F??＝16.988, P＜0.05). Of particular inter-
est, the mean L?of both groups of CS-exposed subjects was signiﬁcantly higher than that in the control animals
(P＜0.05). Also, the density and tissue loss of alveolar septa of both CS-exposed groups were signiﬁcant as shown by the decreases in V???and S????(P＜0.05).
When we compared the results of treated and untreated groups,we found the airspace enlargement and tissue loss of untreated animals were signiﬁcantly worse than that in treated rats. That is to say, mean L?of untreated rats was signiﬁcantly higher and mean V???, S????of same group was signiﬁcantly lower than that of the MK-treated animals. All measurements including L?, V???and S????of all groups are listed in Table 1. These results indicated that exposure to CS led to the thinning of alveolar septa, increased alveolar airspace and tissue loss and that treatment with MK protected against those changes.
There was a signiﬁcant diﬀerence in the mean total LMC counts of both CS-exposed groups and the controls(F??＝14.947,
P＜0.05) (Table 2). Also, there was a signiﬁcant
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 diﬀerence in the proportion of degranulated LMC among the groups (F??＝19.668, P＜0.05). That is, both CS-exposed groups had higher LMC and proportion of degranulated LMC than that in controls (Table 2).
However, there was no signiﬁcant diﬀerence between the mean total LMC and the degranulated LMC ratio of untreated and treated CS-exposed groups (P＞0.05)
(Table 2). We observed an increased LMC density in the subpleural area of lungs of the CS-exposed rats;how-
ever, there was no signiﬁcant heterogeneity or increased number of LMC in the control group. An“intact”and
“degranulated”LMC are shown in Fig. 1.
Discussion
 
This study provides in vivo evidence of the protective eﬀect of the LTR-1AT montelukast on CS-induced injury within the lungs of CS-exposed rats. We demonstrate that MK treatment was associated with fewer alveolar airspace enlargements and less tissue loss, which are the accepted criteria showing CS-induced lung injury. In addition, although the diﬀerences were not statistically signiﬁcant, we found that MK-treated rats had fewer LMC(which is the most important source of LTs in the lungs)and lower activation than that in subjects treated with saline.
Fig.1  Histopathology of lungs and mast cells. (a)In control rats, there was no sign of pulmonary inﬂammation or degeneration in histopathology of the lungs(haemotoxylin-eosin, ×40). (b)In cigarette smoking-exposed untreated rats, most of the alveoli were distorted,
with alveolar septal attenuation, airspace enlargement and tissue loss(haemotoxylin-eosin,×40). (c)Alveolar distortion, septal attenuation and tissue loss in rats treated with MK were not as severe as that in members of the untreated CS-exposed group(haemotoxylin-eosin,×40).









L?(mm)? 83.8±27.2  61.8±21.6  28.3±9.6 ＜0.05 V???(%)? 18.2±4.1  22.1±3.9  29.1±5.7 ＜0.05 S????(mm??)? 0.13±0.05  0.18±0.04  2.11±0.06 ＜0.05
?, Linear intercept of alveolar septa;?, volume density of alveolar septa;?, density of the alveolar surface area per unit volume of lung parenchyma;?, P value is signiﬁcant if less than 0.05. φ, The diﬀerences between the same parameters of each group by post hoc test
(Tukey-Multiple Comparisons Test)were signiﬁcant.
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 Leukotrienes are derived from arachidonic acid of membrane lipids by 5-LO and play many roles in the pathogenesis of asthma and other pulmonary diseases by their bronchoconstrictor and inﬂammatory eﬀects［11］.
They increase vascular permeability by the exudation of plasma into the airway wall and lumen, which are impor-
tant pathological features of COLD and bronchial asthma
［11, 18］. Leikauf et al. showed that LTs［exhibit］
potent harmful eﬀects on pulmonary epithelial cells, and McAlexander et al. showed that LTs exacerbate the sensitizing eﬀects of epithelial and alveolar wall denudation by stimulating local aﬀerent nerves to release tachykinines,
increasing plasma exudation and vascular permeability
［19, 20］. Moreover, several studies suggested that LTs are potent chemoattractants for inﬂammatory cells to lung parenchyma. Laitinen et al. demonstrated that LTs are capable of recruiting granulocytes, particularly eosino-
phils, into the lamina propria［21］. Also, Calhoun et al.
and Diamant et al. showed that LTs led to granulocyte and basophil accumulation in the lung［22, 23］.
Nakamura et al. believe that LTs cause T- and B-lymphocytes inﬁltration into the pulmonary parenchyma
［24］. CS exposure is a major risk factor for 2 diﬀerent disorders of 2 diﬀerent age groups, and both disorders may be called CSLD. The ﬁrst is the occurrence of wheeze and airway hyperreactivity or asthma related to passive CS exposure in childhood, and the second is COLD related to active CS in adulthood. Despite our understanding of the immunopathogenesis and cellular mechanisms of asthma and wheeze as inﬂammatory disease, the cellular and molecular mechanisms of COLD have been neglected until recently. Although these types of inﬂammation diﬀer markedly;both diseases are char-
acterized by chronic inﬂammation of the airways and pulmonary parenchyma of the lungs［25］. Both disorders have identical inﬂammatory cell inﬁltration such as in-
creased mast cells, neutrophils, eosinophils, lymphocytes
 
and macrophages［25］. While bronchial asthma and recurrent wheeze are characterized by an increase in CD4
＋Th2 lymphocytes, mast cells, neutrophils and activat-
ed eosinophils in bronchial biopsies, the pathology of COLD has been shown as an increase in the proportion of mast cells, neutrophils, CD8-T-lymphocytes and macrophages in the lung parenchyma［25, 26］. All these inﬂammatory cells and bronchial epithelial cells are the main source of LTs in lungs［8, 9, 11］. Also, increased mast cells, neutrophils, eosinophils, lymphocytes and macrophages are clearly evident and activation has been proven in the bronchioli and pulmonary parenchyma in active and passive smokers［4, 5］. An important obser-
vation reported by Fauler and Frolich demonstrated that CS exposure causes a dose-related increase in LTs production in smokers［7］. The authors claimed that some of the adverse eﬀects of CS exposure in the CS-induced lung injury might be related to enhanced LTs synthesis［7］. Our results support this observation, as evidenced by the fact that LTR-1AT treatment with MK was associated with signiﬁcantly diminished CS-induced lung injury demonstrated by morphometric measurements.
This evidence is also supported by previous studies using anti-inﬂammatory treatment with LTR-1AT, which inhib-
ited the accumulation of mast cells/basophils, eosinophils,
basophils, T-and B-lymphocytes and neutrophils into the lung parenchyma. Moreover, the increased plasma exuda-
tion and pulmonary epithelial denudation, which are the main causes of pathological changes in CS exposure-
induced lung injury have been proven［20, 23, 24］.
Lung mast cells are mononuclear cells and are almost exclusively localized to lung tissues［27］. The capacity of LMC to release plenty of powerful inﬂammatory media-
tors makes this cell a unique member of the lung’s immune response network［27］. These mediators are usually released within minutes after activation. These inﬂammatory mediators or cytokines and chemical sub-










LMC?count(mm?) 20.1±3.4# 17.2±3.8# 7.3±2.1? ＜0.05 Degranulated LMC(%) 23.2±6.3# 20.7±4.9# 9.1±2.9? ＜0.05
?P value is signiﬁcant if less than 0.05;?, lung mast cell.?, the diﬀerences between#symbols were not signiﬁcant and between#and?were signiﬁcant.
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stances, such as LTB4, PgD2, TxA2, PAF, IL-8,
IL-5, TNF-α, TGF-β, tyriptase, elastase and β-
glucronidase, have clearly harmful and degenerative eﬀects on lung parenchyma［28］. One group of these inﬂammatory mediators is LTs, which are classiﬁed as nonpreformed or newly synthesized mediators. LMC is a major pulmonary cellular source of LTs［11, 27］. The eﬀects of LTs on CS-induced lung injury were discussed above. Several studies reported that, indeed, the number of mast cells in the lungs of smokers was signiﬁcantly increased compared to that of non-smokers. Experimental studies showed an increase of mast cell density and degranulation rate in CS-exposed animals［4, 17, 29］.
Knowing this causes us to hypothesize that CS may increase the number and the activation of LMC, which may contribute to CS-induced lung injury by increasing production of LTs in the lung parenchyma. Our results showed that CS-exposed rats had signiﬁcantly increased LMC count and activation compared to control subjects.
Although there was no signiﬁcant correlation between LMC count and degranulation ratio as an activation criteria of mast cells in MK-treated and untreated groups,
we demonstrated that CS-induced lung injury was clearly diminished in MK-treated rats by blocking the activity of LTs using the LTR-1AT montelukast. Calhoun and coworkers reported that LTR-1AT inhibited the rise in basophils, which resemble mast cells, in asthmatic patients［23］. In our study, despite the fact that LMC count and degranulation ratio of MK-treated rats were lower than that in untreated CS-exposed rats, the diﬀerence was not statistically signiﬁcant. Therefore, we cannot claim with certainty that LTR-1AT inhibits the rises in number and activation of LMC due to CS exposure.
We showed that treatment with MK, a potent LTR-
1AT, is protective against pathological changes such as alveolar airspace enlargement and tissue loss secondary to CS exposure. It is well known that LTR-1AT has anti-inﬂammatory eﬀects during both early and late phases of inﬂammation［12］. Therefore, we suggest that LTR-
1AT may have a protective eﬀect against smoking-
induced acute lung injury and late-phase chronic degenera-
tion due to CS-induced chronic persistent inﬂammatory processes in the lungs. Further studies are needed to clarify the mechanism of the eﬀect of leukotrienes receptor antagonists.
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